Related references
Note: Only part of the references are listed.Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study
Michael Andersson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer
Francisco J. Esteva et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
Katrina Bauer et al.
BMC CANCER (2010)
Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2010)
Selection Bias Clouds Apparent Benefit of Longer Hormone Duration
Kevin Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Metastatic Behavior of Breast Cancer Subtypes
Hagen Kennecke et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Jeffrey R. Infante et al.
CLINICAL BREAST CANCER (2009)
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)
G. Schilling et al.
INVESTIGATIONAL NEW DRUGS (2009)
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
Harold J. Burstein et al.
CANCER (2007)
A review of the use of trastuzumab (Herceptin®) plus vinorelbine in metastatic breast cancer
A. Chan
ANNALS OF ONCOLOGY (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer
Lyndsay N. Harris et al.
CLINICAL CANCER RESEARCH (2007)
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial
A. Chan et al.
BRITISH JOURNAL OF CANCER (2006)
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer
Nicholas Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
MD Pegram et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
HJ Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer
M Jahanzeb et al.
ONCOLOGIST (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
